Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194732 | 0.82 | KDM4E (0.48) | KMT2ALMNATSHRKDM4EALDH1A1 | |
| SCHEMBL29882404 | 0.78 | PIM1 (0.42) | PTPN1KMT2APIM1PLK4AURKA | |
| SCHEMBL23030103 | 0.78 | PIM1 (0.42) | PTPN1KMT2APIM1PLK4AURKA | |
| SCHEMBL31228792 | 0.76 | PIM1 (0.41) | APPPTPN1KMT2APIM1GRM2 | |
| SCHEMBL16505348 | 0.76 | PIM1 (0.41) | APPPTPN1KMT2APIM1GRM2 | |
| SCHEMBL153746 | 0.76 | RAB9A (0.41) | PTPN1KMT2APIM1MAPK1GRM2 | |
| SCHEMBL22912766 | 0.76 | MAPK1 (0.47) | KMT2ALCKMAPK1IRAK4KDM4E | |
| SCHEMBL29790212 | 0.76 | MAPK1 (0.47) | KMT2ALCKMAPK1IRAK4KDM4E | |
| SCHEMBL16421176 | 0.76 | PTPN1 (0.47) | PTPN1KMT2AKDRSCN9ACCNC | |
| SCHEMBL21550811 | 0.72 | MEN1 (0.33) | KMT2APIM1PLK4CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | claimed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | claimed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | claimed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | claimed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | claimed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | claimed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | claimed |
| WO-2015082357-A1 | S1P3 ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2015-06-11 | — | — | WO | claimed |
| EP-2878339-A1 | SIP3 antagonists | Siena Biotech S.p.A. (IT) | 2015-06-03 | — | — | EP | claimed |
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | disclosed |
| US-11472772-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2022-10-18 | — | — | US | disclosed |
| EP-3896068-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2021-10-20 | — | — | EP | disclosed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | disclosed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | disclosed |
| US-20180201582-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-07-19 | — | — | US | disclosed |
| US-9951017-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2018-04-24 | — | — | US | disclosed |
| EP-3086845-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2016-11-02 | — | — | EP | disclosed |
| US-20160297762-A1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2016-10-13 | — | — | US | disclosed |
| WO-2015082357-A1 | S1P3 ANTAGONISTS | SIENA BIOTECH S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
| EP-2878339-A1 | SIP3 antagonists | Siena Biotech S.p.A. (IT) | 2015-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201582-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | APP 28/4885PTPN1 2961/4885KMT2A 2731/4885 |
| US-20160297762-A1 | S1P3 ANTAGONISTS | S1PR3, S1PR5, S1PR1 | APP 28/4885PTPN1 2961/4885KMT2A 2731/4885 |
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | APP 28/4885PTPN1 2961/4885KMT2A 2731/4885 |
| US-20200157052-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | APP 28/4885PTPN1 2961/4885KMT2A 2731/4885 |
| US-11472772-B2 | S1P3 antagonists | S1PR3, S1PR5, S1PR1 | APP 28/4885PTPN1 2961/4885KMT2A 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.